Emergent BioSolutions reports third-quarter 2026 net loss of $32.7 million
Emergent BioSolutions reported Q3 2026 total revenues of $110.0 million but swung to a net loss of $32.7 million. The company also announced a $75 million repurchase of Senior Unsecured Notes and updated its leadership structure.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed